2.3600
-0.0500
(-2.07%)
At close: January 10 at 4:00:01 PM EST
2.3508
-0.01
(-0.39%)
After hours: January 10 at 6:39:26 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
10,091.0000
1,698.0000
6,194.0000
1,507.0000
242.0000
Operating Expense
228,287.0000
177,226.0000
149,087.0000
141,881.0000
168,387.0000
Operating Income
-218,196.0000
-175,528.0000
-142,893.0000
-140,374.0000
-168,145.0000
Net Non Operating Interest Income Expense
-42,339.0000
-31,562.0000
-7,197.0000
-843.0000
536.0000
Other Income Expense
-9,650.0000
-1,312.0000
1,523.0000
-821.0000
1,352.0000
Pretax Income
-270,185.0000
-208,402.0000
-148,567.0000
-142,038.0000
-166,257.0000
Tax Provision
42.0000
-19.0000
272.0000
58.0000
-24,163.0000
Net Income Common Stockholders
-270,227.0000
-208,383.0000
-148,839.0000
-142,096.0000
-142,094.0000
Diluted NI Available to Com Stockholders
-270,227.0000
-208,383.0000
-148,839.0000
-142,096.0000
-142,094.0000
Basic EPS
-1.22
-1.20
-1.57
-1.97
-2.76
Diluted EPS
-1.22
-1.20
-1.57
-1.97
-2.76
Basic Average Shares
232,134.3170
173,941.9260
94,993.4000
72,084.0780
51,558.0750
Diluted Average Shares
232,134.3170
173,941.9260
94,993.4000
72,084.0780
51,558.0750
Total Expenses
228,287.0000
177,226.0000
149,087.0000
141,881.0000
168,387.0000
Net Income from Continuing & Discontinued Operation
-270,227.0000
-208,383.0000
-148,839.0000
-142,096.0000
-142,094.0000
Normalized Income
-260,804.7500
-204,210.3805
-148,421.8500
-141,548.4400
-142,094.0000
Interest Income
27,918.0000
13,505.0000
1,708.0000
262.0000
536.0000
Interest Expense
70,257.0000
45,067.0000
8,905.0000
1,105.0000
--
Net Interest Income
-42,339.0000
-31,562.0000
-7,197.0000
-843.0000
536.0000
EBIT
-199,928.0000
-163,335.0000
-139,662.0000
-140,933.0000
-166,257.0000
EBITDA
-192,514.0000
-156,770.0000
-132,240.0000
-132,475.0000
-160,599.0000
Reconciled Depreciation
7,414.0000
6,565.0000
7,422.0000
8,458.0000
5,658.0000
Net Income from Continuing Operation Net Minority Interest
-270,227.0000
-208,383.0000
-148,839.0000
-142,096.0000
-142,094.0000
Total Unusual Items Excluding Goodwill
-12,563.0000
-4,173.0000
-515.0000
-676.0000
--
Total Unusual Items
-12,563.0000
-4,173.0000
-515.0000
-676.0000
--
Normalized EBITDA
-179,951.0000
-152,597.0000
-131,725.0000
-131,799.0000
-160,599.0000
Tax Rate for Calcs
0.0003
0.0000
0.0002
0.0002
0.0001
Tax Effect of Unusual Items
-3,140.7500
-0.3805
-97.8500
-128.4400
--
12/31/2020 - 6/22/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DAWN Day One Biopharmaceuticals, Inc.
11.80
-3.28%
FATE Fate Therapeutics, Inc.
1.4650
-12.28%
ALLO Allogene Therapeutics, Inc.
2.0550
-12.55%
BRNS Barinthus Biotherapeutics plc
1.0300
-9.65%
KYTX Kyverna Therapeutics, Inc.
3.4500
-9.21%
ADAP Adaptimmune Therapeutics plc
0.6200
+0.02%
NUVB Nuvation Bio Inc.
2.7800
-7.64%
ATRA Atara Biotherapeutics, Inc.
15.55
-5.93%
ANNX Annexon, Inc.
4.8300
-0.21%
AGIO Agios Pharmaceuticals, Inc.
34.42
-4.12%